Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Portfolio Pulse from
Mallinckrodt presented data on TERLIVAZ® (terlipressin) for treating hepatorenal syndrome (HRS) at the AASLD Annual Meeting. TERLIVAZ is the only FDA-approved drug for improving kidney function in HRS patients, a rare and severe condition.
November 18, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mallinckrodt's presentation of TERLIVAZ® at the AASLD meeting highlights its unique position as the only FDA-approved treatment for HRS, potentially boosting its market presence.
The presentation at a major medical conference like AASLD can increase awareness and credibility of TERLIVAZ®, potentially leading to higher adoption rates. As the only FDA-approved treatment for HRS, this could positively impact Mallinckrodt's market position and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90